{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:46:15Z","timestamp":1792125975836,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"DOI":"10.1007\/s00204-026-04584-9","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:08:15Z","timestamp":1792123695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["N-nitroso-hydrochlorothiazide: in vivo mutagenicity evaluation in a transgenic rodent model"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4843-6713","authenticated-orcid":false,"given":"Gregory R.","family":"Ott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Bebb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marinkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safra","family":"Rudnic-Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojdeh","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Niddam-Hildesheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"4584_CR1","unstructured":"Algina J (2005) Aspin\u2013Welch Test. https:\/\/api.semanticscholar.org\/CorpusID:118146341. Accessed 6 Feb 2024"},{"key":"4584_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/01.HYP.22.3.388","volume":"22","author":"KH Beyer","year":"1993","unstructured":"Beyer KH (1993) Chlorothiazide. How the thiazides evolved as antihypertensive therapy. Hypertension 22:388\u2013391","journal-title":"Hypertension"},{"key":"4584_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jmms12010026","volume":"12","author":"NM Blebea","year":"2025","unstructured":"Blebea NM, Pu\u0219ca\u0219u C et al (2025) Diuretic Therapy : Mechanisms, Clinical Applications, and Management. J Mind Med Sci 12:26. https:\/\/doi.org\/10.3390\/jmms12010026","journal-title":"J Mind Med Sci"},{"key":"4584_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/em.22618","volume":"65","author":"J Cheung","year":"2024","unstructured":"Cheung J, Dobo K, Zhang et al (2024) Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential. Environ Mol Mutagen 65:203\u2013221. https:\/\/doi.org\/10.1002\/em.22618","journal-title":"Environ Mol Mutagen"},{"key":"4584_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2307\/3001616","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG (1954) Some Methods of Strengthening the Common Chi-Square Test. Biometrics 10:417\u2013451. https:\/\/doi.org\/10.2307\/3001616","journal-title":"Biometrics"},{"key":"4584_CR6","unstructured":"EFPIA (2022) Position Paper: Hydrochlorothiazide HCTZ- Investigation into potential N-Nitrosation and the specific nature of Nitroso HCTZ. https:\/\/www.efpia.eu\/media\/677180\/white-paper-version-2-16-06-2022.pdf"},{"key":"4584_CR7","unstructured":"EMA (2025) Questions and answers on Information on nitrosamines for marketing authorisation holders (EMA\/409815\/2020). https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf"},{"key":"4584_CR8","unstructured":"FDA (2024) Guidance for Industry: Control of Nitrosamine Impurities in Human Drugs. Revision 2. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/control-nitrosamine-impurities-human-drugs"},{"key":"4584_CR9","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1007\/s00204-024-03859-3","volume":"98","author":"RD Gandhi","year":"2024","unstructured":"Gandhi RD, Hickert S, Hoevelman Y et al (2024) Escaping the cohort of concern. Arch Toxicol 98:4159\u20134172. https:\/\/doi.org\/10.1007\/s00204-024-03859-3","journal-title":"Arch Toxicol"},{"key":"4584_CR10","doi-asserted-by":"publisher","first-page":"105245","DOI":"10.1016\/j.yrtph.2022.105245","volume":"134","author":"S Glowienke","year":"2022","unstructured":"Glowienke S, Onken U et al (2022) Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity. Regul Toxicol Pharmacol 134:105245. https:\/\/doi.org\/10.1016\/j.yrtph.2022.105245","journal-title":"Regul Toxicol Pharmacol"},{"key":"4584_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0041-008x(77)90124-7","volume":"40","author":"B Gold","year":"1977","unstructured":"Gold B, Mirvish SS (1977) N-Nitroso derivatives of hydrochlorothiazide, niridazole, and tolbutamide. Toxicol Appl Pharmacol 40:131\u2013136. https:\/\/doi.org\/10.1016\/0041-008x(77)90124-7","journal-title":"Toxicol Appl Pharmacol"},{"key":"4584_CR13","first-page":"326","volume":"14","author":"JA Gossen","year":"1993","unstructured":"Gossen JA, Vijg J (1993) A selective system for lacZ phage using a galactose-sensitive E. coli host. Biotechniques 14:326\u2013330","journal-title":"Biotechniques"},{"key":"4584_CR12","doi-asserted-by":"publisher","first-page":"7971","DOI":"10.1073\/pnas.86.20.7971","volume":"86","author":"JA Gossen","year":"1989","unstructured":"Gossen JA, de Leeuw W, Tan CH et al (1989) Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci U S A 86:7971\u20137975. https:\/\/doi.org\/10.1073\/pnas.86.20.7971","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4584_CR14","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1021\/acs.oprd.3c00119","volume":"27","author":"R Grahek","year":"2023","unstructured":"Grahek R, Drev M, Zupan\u010di\u010d B et al (2023) Stability and Degradation Pathways of N-Nitroso-Hydrochlorothiazide and the Corresponding Aryl Diazonium Ion. Org. Process Res Dev 27:1792\u20131811. https:\/\/doi.org\/10.1021\/acs.oprd.3c00119","journal-title":"Process Res Dev"},{"key":"4584_CR15","unstructured":"Health Canada (2026) Guidance on Nitrosamine Impurities in Medications. https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/nitrosamine-impurities\/medications-guidance\/nitrosamine-impurities-medications-guidance.pdf"},{"key":"4584_CR18","unstructured":"ICH (2025) Final Concept Paper Addendum to ICH M7 on Risk Assessment and Control of N-Nitrosamine Impurities"},{"key":"4584_CR17","unstructured":"ICH (2023) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. M7(R2)"},{"key":"4584_CR16","unstructured":"ICH (2006) Impurities in new drug substances Q3A(R2) and Impurities in new drug products Q3B(R2)"},{"key":"4584_CR20","doi-asserted-by":"publisher","first-page":"105672","DOI":"10.1016\/j.yrtph.2024.105672","volume":"152","author":"RA Jolly","year":"2024","unstructured":"Jolly RA, Cornwall PD, Noteboom J et al (2024) Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine. Regul Toxicol Pharmacol 152:105672. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105672","journal-title":"Regul Toxicol Pharmacol"},{"key":"4584_CR19","doi-asserted-by":"publisher","unstructured":"Jolly RA, Trejo-Martin A, Bercu JP et al (2026) Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data. Regul Toxicol Pharmacol 106051. https:\/\/doi.org\/10.1016\/j.yrtph.2026.106051","DOI":"10.1016\/j.yrtph.2026.106051"},{"key":"4584_CR21","unstructured":"Kane SP (2025) ClinCalc DrugStats Database, Version 2025.08. ClinCalc. https:\/\/clincalc.com\/Drugstats Updated August 10, 2025. Accessed June 4, 2026"},{"key":"4584_CR22","doi-asserted-by":"publisher","first-page":"105640","DOI":"10.1016\/j.yrtph.2024.105640","volume":"150","author":"NL Kruhlak","year":"2024","unstructured":"Kruhlak NL, Schmid M, Froetschl R et al (2024) Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regul Toxicol Pharmacol 150:105640. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105640","journal-title":"Regul Toxicol Pharmacol"},{"key":"4584_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2005.04.002","volume":"590","author":"IB Lambert","year":"2005","unstructured":"Lambert IB, Singer TM, Boucher SE, Douglas GR (2005) Detailed review of transgenic rodent mutation assays. Mutat Res 590:1\u2013280. https:\/\/doi.org\/10.1016\/j.mrrev.2005.04.002","journal-title":"Mutat Res"},{"issue":"5","key":"4584_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/mutage\/4.5.327","volume":"4","author":"L Migliore","year":"1989","unstructured":"Migliore L, Ventura L, Barale R et al (1989) Micronuclei and nuclear anomalies induced in the gastro-intestinal epithelium of rats treated with formaldehyde. Mutagenesis 4(5):327\u2013334. https:\/\/doi.org\/10.1093\/mutage\/4.5.327","journal-title":"Mutagenesis"},{"key":"4584_CR26","unstructured":"Ministry of the Environment (MOE) (2014) Act on Welfare and Management of Animals (Act No. 105 of October 1, 1973). Latest revision: Act No. 46, Japan. [30 pp.] Accessed 23 Oct 2024"},{"key":"4584_CR24","unstructured":"Ministry of the Environment (MOE) (2013) Standards Relating to the Care and Keeping and Reducing Pain of Laboratory Animals (Notice of the Ministry of the Environment 88 of 2006). Latest Revision: Notice of the Ministry of the Environment 84, Japan. [7 pp.]. Accessed 23 Oct 2024"},{"key":"4584_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/1755-5922.12015","volume":"31","author":"JM Neutel","year":"2013","unstructured":"Neutel JM, Smith DH (2013) Hypertension management: Rationale for Triple Therapy Based on Mechanisms of Action Cardiovasc. Ther 31:251\u2013258. https:\/\/doi.org\/10.1111\/1755-5922.12015","journal-title":"Ther"},{"key":"4584_CR29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","volume":"27","author":"R Nudelman","year":"2023","unstructured":"Nudelman R, Kocks G, Mouton B, Ponting DJ, Schlingemann J, Simon S, Smith GF, Teasdale A, Werner AL (2023) The Nitrosamine Saga: Lessons Learned from Five Years of Scrutiny. Org. Process Res Dev 27:1719\u20131735. https:\/\/doi.org\/10.1021\/acs.oprd.3c00100","journal-title":"Process Res Dev"},{"key":"4584_CR30","unstructured":"OECD (2022) Test No, vol 488. Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays"},{"key":"4584_CR31","doi-asserted-by":"publisher","first-page":"106009","DOI":"10.1016\/j.yrtph.2025.106009","volume":"166","author":"DJ Ponting","year":"2026","unstructured":"Ponting DJ, Silveira GO, Rowell P, Heghes CI, Fowkes A, Barber CG (2026) Establishing best practice for N-nitrosamine read-across and surrogate selection. Regul Toxicol Pharmacol 166:106009. https:\/\/doi.org\/10.1016\/j.yrtph.2025.106009","journal-title":"Regul Toxicol Pharmacol"},{"key":"4584_CR32","doi-asserted-by":"publisher","first-page":"105681","DOI":"10.1016\/j.yrtph.2024.105681","volume":"152","author":"MW Powley","year":"2024","unstructured":"Powley MW, Sobol Z, Johnson GE et al (2024) N-nitrosamine impurity risk assessment in pharmaceuticals: Utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP. Regul Toxicol Pharmacol 152:105681. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105681","journal-title":"Regul Toxicol Pharmacol"},{"key":"4584_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/em.70012","author":"JM Roper","year":"2025","unstructured":"Roper JM, Griffin T, Johnson G et al (2025) Using N-nitrosodiethanolamine (NDELA) and N-nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency-Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity Data. Environ Mol Mutagen. https:\/\/doi.org\/10.1002\/em.70012","journal-title":"Environ Mol Mutagen"},{"key":"4584_CR34","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1007\/s00204-025-04103-2","volume":"99","author":"S Simon","year":"2025","unstructured":"Simon S, Schlingemann J, Johnson G et al (2025) Deriving safe limits for N-nitroso-bisoprolol by error-corrected next-generation sequencing (ecNGS) and benchmark dose (BMD) analysis, integrated with QM modeling and CYP-docking analysis. Arch Toxicol 99:3935\u20133962. https:\/\/doi.org\/10.1007\/s00204-025-04103-2","journal-title":"Arch Toxicol"},{"key":"4584_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3109\/10408444.2014.925424","volume":"44","author":"W Slob","year":"2014","unstructured":"Slob W (2014) Benchmark Dose and the Three Rs. Part II. Consequences for study design and animal use. Crit Rev Toxicol 44:568\u2013580. https:\/\/doi.org\/10.3109\/10408444.2014.925424","journal-title":"Crit Rev Toxicol"},{"key":"4584_CR36","unstructured":"Snedecor GW, Cochran WG (1991) Statistical Methods, 8th edn. Iowa State University"},{"key":"4584_CR37","doi-asserted-by":"publisher","first-page":"105403","DOI":"10.1016\/j.yrtph.2023.105403","volume":"141","author":"DJ Snodin","year":"2023","unstructured":"Snodin DJ (2023) Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines. Regul Toxicol Pharmacol 141:105403. https:\/\/doi.org\/10.1016\/j.yrtph.2023.105403","journal-title":"Regul Toxicol Pharmacol"},{"key":"4584_CR38","volume-title":"The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)","author":"WHO, World Health Organization","year":"2023","unstructured":"WHO, World Health Organization (2023) The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). World Health Organization, Geneva. https:\/\/hdl:10665\/371090.WHO\/MHP\/HPS\/EML\/2023.02"},{"key":"4584_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/em.70007","volume":"66","author":"S Zhang","year":"2025","unstructured":"Zhang S, Cheung J, Kostal J, Voutchkova-Kostal A, Schuler M (2025) Re-Evaluating Acceptable Intake: A Comparative Study of N-Nitrosomorpholine and N-Nitroso Reboxetine Potency Environ. Mol Mutagen 66:80\u201398. https:\/\/doi.org\/10.1002\/em.70007","journal-title":"Mol Mutagen"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04584-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-026-04584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:08:17Z","timestamp":1792123697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-026-04584-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":38,"alternative-id":["4584"],"URL":"https:\/\/doi.org\/10.1007\/s00204-026-04584-9","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The manuscript does not contain clinical studies or patient data. All animal studies were conducted in accordance with regional animal welfare guidelines and standards for the care and management of laboratory animals, and the study protocols were reviewed and approved by the test facility institutional animal care and use committee (IACUC) prior to initiation.","order":1,"name":"Ethics","label":"Compliance with ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.R. Ott, T. Griffin, K. Bebb, M. Marinkovic, R. Nudelman, J.M. Roper, S. Rudnic-Glick, T. Szabo, M. Yousefi, and V. Niddam-Hildesheim are or were employees and are shareholders of Teva Pharmaceutical Industries, a maker of human medicinal products.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}